Classen Immunotherapies Inc. Release: More Proof Published That Common Childhood Vaccines Are The Cause Of The Diabetes Epidemic, Data Identifies Children Eligible For Compensation

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

http://www.biospace.com/news_story.cfm?StoryID=12782920

Classen Immunotherapies Inc. Release: More Proof Published That Common Childhood Vaccines Are The Cause Of The Diabetes Epidemic, Data Identifies Children Eligible For Compensation
 

BALTIMORE, May 27 /PRNewswire/ -- The prestigious peer reviewed journal, Journal of Pediatric Endocrinology and Metabolism published a study this week by Dr. J. Bart Classen, an immunologist at Classen Immunotherapies, and David Carey Classen, an infectious disease specialist at the University of Utah, providing support for a causal relationship between several common pediatric vaccines and the development of insulin dependent diabetes. Their previously published work proved the hemophilus vaccine, a common pediatric vaccine, caused a 25% rise in insulin dependent diabetes in children under the age of 7. Classen's research indicates most cases of diabetes caused by vaccines occur between 24 to 48 months after immunization of young children but the delay can be shorter in older children with prior damage to their pancreas. The time delay between vaccination and diabetes corresponds exactly to work from several independent groups which showed a similar delay between the initiation of autoimmunity to the insulin secreting islet cells and the development of diabetes.

(See Story from BioSpace.com) (5/27/03)

Related Companies

Related News

Related Clinical Development Pipelines

Patients:

  • See Clinical Research Studies currently enrolling patients for Diabetes
     
  • See Clinical Research Studies currently enrolling patients for Children's Health (misc)
     

BioSpace News Reader

     

  • > Next story: Abbott Laboratories (ABT) Presents New HUMIRA(TM) (adalimumab) Data Showing Effectiveness In Adult Rheumatoid Arthritis Patients With Early And Established Disease And Sustained Response Up To Four Years

 

 

 

Return to Vaccination News Home Page

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.